BRISTOL MYERS SQUIBB CO(BMY)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
BRISTOL MYERS SQUIBB CO (BMY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BMY at 70.4/100 on a 32-signal composite quality model, placing it at rank #219 of 2,961 stocks — the top 10% of the AI-ranked universe. BMY scores in the top quartile across revenue scale (96.8), balance sheet strength (85.5), profitability (82.5). Areas of concern include revenue growth (34.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), BRISTOL MYERS SQUIBB CO reports quarterly revenue of $13.0B, net income of $3.3B, free cash flow of $3.1B. Top institutional holders of BMY by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. BMY trades on the NYSE exchange and files with the SEC under CIK 14272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BRISTOL MYERS SQUIBB CO directly from SEC EDGAR.
AI Quality Score
70.4/100
AI Rank
#219
Revenue
$13.0B
Net Income
$3.3B
Free Cash Flow
$3.1B
BMY key financials by period
BRISTOL MYERS SQUIBB CO reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$48.2B
$7.1B
19.4%
FY 2024
10-K
$48.3B
$-8.9B
-17.3%
FY 2023
10-K
$45.0B
$8.0B
18.8%
FY 2022
10-K
$46.2B
$6.3B
16.7%
FY 2021
10-K
$46.4B
$7.0B
17.5%
FY 2020
10-K
$42.5B
$-9.0B
-16.2%
Institutions holding BMY
Institutional investors reporting a position in BRISTOL MYERS SQUIBB CO on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue rose 6% to $12,973 million as the Growth Portfolio gained 15% and Eliquis 22%, while GAAP EPS jumped to $1.62 from $0.64.
Biggest Revenue Drivers
Growth Portfolio$7,560M+15% YoY
Higher demand and higher average net selling prices across the Growth Portfolio
Legacy Portfolio$5,422M-4% YoY
Impact of generics across the remainder of the Legacy Portfolio, partly offset by Eliquis
Biggest Revenue Drivers
Total revenue: $12,973M+6% YoY
Growth Portfolio$7,560M+15% YoY
Higher demand and higher average net selling prices across the Growth Portfolio
Within Growth Portfolio
Opdivo$2,485M-3% YoY
Lower U.S. demand reflecting greater utilization of Opdivo Qvantig
Legacy Portfolio$5,422M-4% YoY
Impact of generics across the remainder of the Legacy Portfolio, partly offset by Eliquis
Within Legacy Portfolio
Eliquis$4,481M+22% YoY
Higher demand and higher U.S. average net selling prices, as a U.S. list price reduction lowered rebates
Revlimid$425M-49% YoY
Lower U.S. demand as a result of generic erosion, partially offset by higher average net selling prices
Largest Expense Items
Cost of products sold$3,726M+11% YoY
Primarily due to higher alliance profit sharing
Research and development$2,959M+15% YoY
Higher IPRD impairment charges and the $220 million priority review voucher purchase, partly offset by productivity savings
Selling, general and administrative$1,826M+7% YoY
Higher investments in new product launches, partially offset by strategic productivity initiative savings
Amortization of acquired intangible assets$437M-47% YoY
Lower amortization for Pomalyst, whose acquired marketed product right was fully amortized in fourth quarter 2025
Margins: The filing gives no margin metric, but cost of products sold grew 11% versus 6% revenue growth on higher alliance profit sharing. Total GTN adjustments fell to 30% of gross sales from 46%.
Watch Items from the Filing
Receivables from the three largest U.S. customers were 71% of total trade receivables at June 30, 2026, versus 75% at December 31, 2025.
Legacy erosion is accelerating: Pomalyst/Imnovid -71%, Revlimid -49%, Sprycel -27%, Abraxane -47% as generics entered U.S. and EU markets.
Eliquis EU composition-of-matter patents and SPCs expire November 2026; UK generics already marketed, and IRA maximum fair price applied from January 1, 2026.
IPRD impairment charges of $420 million in the quarter ($830 million year-to-date) reflect a partial write-down of an oncology asset on recent clinical results.
New commitments: $600 million Hengrui upfront payable in Q3 2026 plus two $175 million anniversary payments, and $2.0 billion of BioNTech anniversary payments through 2028.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
